Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 576 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... September 21, 2023 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... February 10, 2022 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 New insights on self-sampling for cervical cancer screening April 27, 2022 Load more HOT NEWS £82,000 of Donations Pour in for Mom with Incurable Cancer to... Foodie Friday: What to do with all these zucchini? UK health inequalities: 20,000 more cancer cases a year in the... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ
